Pharmacy's Contribution to Geriatric Care

1981 ◽  
Vol 15 (7-8) ◽  
pp. 569-571 ◽  
Author(s):  
Robert N. Butler

It is clear that we currently lack the scientific knowledge necessary to deal with the vast array of problems, both physical and mental, which so often arise as a result of multipathology and its management by multiple-drug use. This lack of fundamental knowledge in the area of drug use, alteration in drug use, and aging reflects, to some degree, the historical neglect of research on the problems that confront the elderly. Pharmacists can and should take an active part in developing the scientific and clinical data base to ensure better management of drug use among the elderly.

1975 ◽  
Author(s):  
James A. Earles ◽  
Cecil J. Mullins ◽  
James W. Abellera ◽  
Alan E. Michelson
Keyword(s):  
Drug Use ◽  

1990 ◽  
Author(s):  
Joseph M. Harrison ◽  
Peng Chen ◽  
Charles S. Ballentine ◽  
J. Terry Yates
Keyword(s):  

1990 ◽  
Vol 5 (5) ◽  
pp. 301-308
Author(s):  
V Kovess ◽  
M Ortun

SummaryFrench publications on psychotropics are curiously few. Data are available and French consumption of psychotropics, at least minor tranquilizers has been consistently reported as being higher than that found in other countries. The authors attempt to answer three questions: is French consuption of psychotropics really higher than other countries? Who is consuming those drugs? In which context? After having reviewed comparative data on sales, data from population surveys are analysed together with samples of prescriptions by different categories of physicians. It seems likely that French people consume more anxiolytics but this does not apply to other psychotropic drugs. Given the fact that drugs are almost free of charge in France, it is always difficult to discriminate between what has been prescribed and what has been taken. Overconsumption of anxiolytics is due to the overconsumption of the elderly population (over 60). Minor tranquilizers are mainly prescribed by general practitioners for psychological reasons.


Author(s):  
Jessica L. Ryan ◽  
Veronica R. Rosa

Abstract Background Illicit drug use increases visits to the hospital. Research is limited on the costs of these healthcare visits by illicit drug. Methods Florida’s Agency for Health Care Administration’s emergency department and inpatient datasets from 2016 to 2018 were analyzed. Adults who used an illicit drug were included in the study population resulting in 709,658 observations. Cost-to-charge ratios were used to estimate healthcare costs. Linear regression analyzed associations of illicit drugs with total healthcare cost. Results Total healthcare costs are estimated at $6.4 billion over the 3 year period. Medicare paid for the most patient care ($2.16 billion) with Medicaid and commercial insurance each estimated at $1.36 billion. Cocaine (9.25%) and multiple drug use (6.12%) increased the costs of an ED visit compared to a patient with cannabis SUD. Opioids (23.40%) and inhalants use (16.30%) increased the costs of inpatient compared to cannabis SUD. Conclusion Healthcare costs are high of patients with illicit drug SUD and poisoning, over half of which are paid for with tax payer dollars and to an unknown degree hospital write-offs. Injuries and illness of patients using cocaine and multiple drugs are associated with more expensive ED patient care and opioids and inhalants are associated with more expensive inpatient care.


BMJ ◽  
1988 ◽  
Vol 296 (6626) ◽  
pp. 930-930 ◽  
Author(s):  
K. Morgan
Keyword(s):  
Drug Use ◽  

1984 ◽  
Vol 18 (6) ◽  
pp. 525-529 ◽  
Author(s):  
Peter P. Lamy ◽  
Mickey C. Smith ◽  
Thomas R. Sharpe
Keyword(s):  
Drug Use ◽  

Sign in / Sign up

Export Citation Format

Share Document